KROS•benzinga•
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
Summary
BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 10, 2025 by benzinga